Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603)

MLA

A. Sugama, et al. “Regorafenib plus Nivolumab in Patients with Advanced Colorectal or Gastric Cancer: An Open-Label, Dose-Finding, and Dose-Expansion Phase 1b Trial (REGONIVO, EPOC1603).” Annals of Oncology, vol. 30, July 2019, p. iv124. EBSCOhost, https://doi.org/10.1093/annonc/mdz157.006.

APA

A. Sugama, Shota Fukuoka, Yosuke Togashi, Hiroki Hara, Takashi Kojima, Masashi Wakabayashi, A. Sato, Hiroyoshi Nishikawa, Naoki Takahashi, H. Tamura, Daisuke Kotani, Y. Mikamoto, K. Shitara, Akihito Kawazoe, Takako Yoshii, Sachiyo Nomura, & Masako Asayama. (2019). Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). Annals of Oncology, 30, iv124. https://doi.org/10.1093/annonc/mdz157.006

Chicago

A. Sugama, Shota Fukuoka, Yosuke Togashi, Hiroki Hara, Takashi Kojima, Masashi Wakabayashi, A. Sato, et al. 2019. “Regorafenib plus Nivolumab in Patients with Advanced Colorectal or Gastric Cancer: An Open-Label, Dose-Finding, and Dose-Expansion Phase 1b Trial (REGONIVO, EPOC1603).” Annals of Oncology 30 (July): iv124. doi:10.1093/annonc/mdz157.006.